EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies

Bispecific antibodies (BsAbs) are used for relapsed or refractory multiple myeloma (RRMM), but infectious complications remain an important concern. We estimated the reported proportion of all-grade and grade ≥3 infections during teclistamab, talquetamab, and elranatamab treatment.A systematic literature review was conducted with Pubmed to extract data which, included the number of patients, grade ≥ 3 infectious adverse events, and non-grade ≥ 3 infectious adverse events. Analyses were conducted using R software and the meta package. A random effect model was utilized.Eight studies (6 RCTs, 2 retrospective studies) involving 946 patients (teclistamab: 394, talquetamab: 374, elranatamab: 178) were analyzed. Pooled proportion (PP) for teclistamab was 0.517 [95% CI, 0.183-0.837], and grade ≥ 3 was 0.233 [95% CI, 0.058-0.598]. The talquetamab group had a PP of 0.636 [95% CI, 0.305-0.874], and grade ≥ 3 were 0.201 [95% CI, 0.110-0.339], with COVID-19 & pneumonia most reported. For elranatamab, the PP was 0.714 [95% CI, 0.397-0.904], with grade ≥ 3 infections at 0.344 [95% CI, 0.015-0.948]. Common infections were adenovirus, CMV, COVID-19, and pneumocystis jirovecii. Table 2 shows consistently reported AEs amongst the three bispecific antibodies for comparability.Infections were frequently reported, but substantial heterogeneity limits the precision and generalizability of a single pooled estimate. Consistent outcome definitions and follow-up are needed.

Authors

Institutions

Publication Details

Journal
Journal of Investigative Medicine
Published
2026-11-17
DOI
https://doi.org/10.1177/10815589261507073
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies

Sofia Yeremian, Angel Nguyen, Pranati Dharmesh Shah, Mojtaba Akhtari et al.
6 links
Journal of Investigative Medicine
Multiple Myeloma Research and Treatments
article

EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies

Sofia Yeremian, Angel Nguyen, Pranati Dharmesh Shah, Mojtaba Akhtari, Jerry Qi, Daniel Park, Emily Choi, Emily Forte
article en

Abstract

Bispecific antibodies (BsAbs) are used for relapsed or refractory multiple myeloma (RRMM), but infectious complications remain an important concern. We estimated the reported proportion of all-grade and grade ≥3 infections during teclistamab, talquetamab, and elranatamab treatment.A systematic literature review was conducted with Pubmed to extract data which, included the number of patients, grade ≥ 3 infectious adverse events, and non-grade ≥ 3 infectious adverse events. Analyses were conducted using R software and the meta package. A random effect model was utilized.Eight studies (6 RCTs, 2 retrospective studies) involving 946 patients (teclistamab: 394, talquetamab: 374, elranatamab: 178) were analyzed. Pooled proportion (PP) for teclistamab was 0.517 [95% CI, 0.183-0.837], and grade ≥ 3 was 0.233 [95% CI, 0.058-0.598]. The talquetamab group had a PP of 0.636 [95% CI, 0.305-0.874], and grade ≥ 3 were 0.201 [95% CI, 0.110-0.339], with COVID-19 & pneumonia most reported. For elranatamab, the PP was 0.714 [95% CI, 0.397-0.904], with grade ≥ 3 infections at 0.344 [95% CI, 0.015-0.948]. Common infections were adenovirus, CMV, COVID-19, and pneumocystis jirovecii. Table 2 shows consistently reported AEs amongst the three bispecific antibodies for comparability.Infections were frequently reported, but substantial heterogeneity limits the precision and generalizability of a single pooled estimate. Consistent outcome definitions and follow-up are needed.

Journal of Investigative Medicine
Loma Linda University Medical Center (US), University of Nevada, Las Vegas (US), University of California, San Francisco (US), Loma Linda University (US), UCLA Medical Center (US), University of California San Diego (US), Harbor–UCLA Medical Center (US), University of Montana (US)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon